| アブストラクト | Although GLP-1 receptors analogues (RAs) benefits-risks profile has been largely documented in diabetes, higher dosages recently approved in obesity still require further assessment. We describe here the case of a 49-year-old female patient treated with semaglutide for obesity, who presented with Wernicke encephalopathy in a context of iterative vomiting and reduced food intake. Eighteen other cases of Wernicke encephalopathy were reported in literature and in the WHO global safety database (VigiBase). A context of nausea/vomiting or reduced food intake is described in 68% of cases, with weight loss ranging from -3.5 to -13.3 kg/month over 3 to 6 months. Disproportionality analysis in VigiBase showed that Wernicke encephalopathy was disproportionately reported with semaglutide, tirzepatide and the whole GLP-1RAs group. Altogether, this comprehensive analysis supports a safety signal regarding the risk of Wernicke encephalopathy with GLP-1RAs, which requires a prompt assessment, accounting for the growing use of these drugs. |
|---|
| 投稿者 | Gras, Cecile; De Wit, Victoria; Oussedik, Nacima; Daclin, Sylvie; Bourdin, Venceslas; Callot, Delphine; Chegrani, Ghiles; Rives-Lange, Claire; Chouchana, Laurent |
|---|
| 組織名 | Centre Regional de Pharmacovigilance, Service de Pharmacologie perinatale,;pediatrique et adulte, Hopital Cochin, Assistance Publique-Hopitaux de Paris;(AP-HP), Paris, France. cecile.gras@aphp.fr.;Service d'Endocrinologie, Hopital Cochin, APHP.Centre-Universite Paris Cite,;Paris, France.;Service de Pharmacie clinique, Hopital Cochin, APHP.Centre-Universite Paris Cite,;(AP-HP), Paris, France.;Nutrition Department, Assistance Publique Hopitaux de Paris, European Hospital;Georges Pompidou, Paris, France.;HEKA Team, UMR1346 : INRIA, Univ Paris Cite, Inserm, France.;Universite Paris Cite, INSERM UMR-S 1343, Pharmacologie et evaluations des;therapeutiques chez l'enfant et la femme enceinte, Paris, France. |
|---|
